Disentangling the Causal Effects of Education and Participation Bias on Alzheimer Disease Using Mendelian Randomization

Does higher educational attainment genuinely reduce Alzheimer's disease risk, or could research participation bias influence this association? A Mendelian randomization study suggests that the relationship between education and clinically diagnosed Alzheimer's disease persists even after accounting for participation-related factors.

source: Neuro Genetics

Summary

[Posted 14/Nov/2026]

AUDIENCE: Neurology, Psychiatry

KEY FINDINGS: The findings support an association between higher educational attainment and reduced risk of clinically diagnosed AD that persists after accounting for research participation. This suggests that the potential protective effect of education may involve mechanisms beyond differences in study enrollment, including cognitive reserve. The contrasting findings for clinically diagnosed AD and AD/ADRD highlight the importance of outcome definition in genetic epidemiological research. Studies relying partly on family history or proxy diagnoses may be more vulnerable to selection and ascertainment biases than those using confirmed clinical diagnoses.

Clinicians and researchers should interpret epidemiological associations between education and dementia with consideration of potential participation bias and differences in diagnostic ascertainment. Although the study strengthens evidence for an independent relationship between education and clinically diagnosed AD, Mendelian randomization findings do not establish that increasing educational attainment later in life will directly prevent Alzheimer's disease. Further research using more representative populations and stronger multivariable genetic instruments is warranted. An important limitation is that the genetic datasets were restricted to individuals of European ancestry, which may limit generalizability to other populations.

BACKGROUND: Higher educational attainment has consistently been associated with a lower incidence of Alzheimer's disease (AD). However, this relationship may partly reflect selection and participation biases rather than a direct protective effect of education. Individuals with higher educational levels may be more likely to participate in clinical research, while people with cognitive impairment may be less likely to complete assessments or enroll in studies. These differences can distort observed associations between education and AD risk. This study investigated whether the association between educational attainment and AD reflects a genuine causal relationship or is influenced by participation-related biases. Semantic Scholar

DETAILS: Chatterjee and colleagues conducted a two-sample Mendelian randomization (MR) study using genome-wide association study (GWAS) summary statistics to examine the relationships among educational attainment, research participation, and AD. The analysis incorporated genetic data for educational attainment, three measures of research participation, clinically diagnosed AD, and AD and related dementias (AD/ADRD), which included clinical diagnoses and family history information.

Our Most Popular Resources

The investigators used fixed-effects inverse variance-weighted analysis as the primary MR approach. Additional analyses included MR-Egger regression, weighted median and mode-based estimators, bidirectional MR, and multivariable Mendelian randomization (MVMR). These methods were used to assess potential confounding, genetic pleiotropy, reverse causation, and the independent effects of education and participation. The educational attainment dataset included 3,037,499 participants, while the primary participation measure, based on completion of an optional UK Biobank Mental Health Questionnaire, included 451,036 participants. The clinically diagnosed AD dataset included 94,437 participants, and the AD/ADRD dataset included 788,989 participants. All included GWAS cohorts were of European ancestry. Semantic Scholar

Genetically predicted educational attainment was associated with a reduced risk of clinically diagnosed AD. Each additional year of education was associated with lower odds of AD (OR, 0.70; 95% CI, 0.63–0.79; p = 8e-10). This association remained significant after adjustment for participation in the multivariable MR analysis (OR, 0.76; 95% CI, 0.62–0.92; p = 0.006), suggesting that participation bias alone did not explain the protective association. However, educational attainment was also associated with increased odds of AD/ADRD (OR, 1.09; 95% CI, 1.02–1.15; p = 0.006). This finding was not supported by sensitivity analyses, indicating that the association was not robust.

Participation in the optional Mental Health Questionnaire was associated with reduced odds of clinically diagnosed AD (OR, 0.325; 95% CI, 0.128–0.326; p = 0.01). Genetic liability to AD was also associated with reduced participation in the questionnaire, suggesting that disease-related factors may influence research enrollment and contribute to selection bias. After adjustment for education, there was limited evidence that participation independently influenced AD risk (OR, 0.58; 95% CI, 0.22–1.51; p = 0.27). The authors also identified low conditional instrument strength in the multivariable analysis, which limits the precision of causal interpretation. Semantic Scholar

Copyright © Skyscape. All rights reserved.

Source: Chatterjee, A., Cavaillès, C., Davies, N. M., et al. Disentangling the Causal Effects of Education and Participation Bias on Alzheimer Disease Using Mendelian Randomization. XXXX. 2025; 11(6): e200307. Published: December, 2025. DOI: 10.1212/NXG.0000000000200307.



The Developmental Trajectories of Working Memory Updating From Early Childhood to Adolescence: A Meta-Analysis

The subsequent slowing of gains suggests that cognitive development in this domain is nonlinear. Differences across task types are also important when interpreting cognitive assessments, comparing children of different ages, or evaluating developmental interventions. The findings support the use of age-appropriate assessment tools and caution against assuming that all working memory updating tasks measure developmental change in the same way.

source: Br. J. Psychol.

Summary

[Posted 28/Oct/2026]

AUDIENCE: Psychiatry, Pediatrics

KEY FINDINGS: Working memory updating develops substantially during childhood, with the greatest improvements observed between ages 3 and 8. The subsequent slowing of gains suggests that cognitive development in this domain is nonlinear. Differences across task types are also important when interpreting cognitive assessments, comparing children of different ages, or evaluating developmental interventions. The findings support the use of age-appropriate assessment tools and caution against assuming that all working memory updating tasks measure developmental change in the same way.

BACKGROUND: Working memory updating is an executive cognitive function that enables individuals to replace outdated information with relevant new information. It supports learning and academic achievement, but its development across childhood and adolescence-and the extent to which developmental patterns differ by assessment task-has not been fully characterized.

DETAILS: Ye Song and Chen Cheng conducted a meta-analysis of 99 studies involving 35,858 participants aged 3-17 years. The analysis examined age-related changes in working memory updating across different assessment paradigms and compared linear and quadratic models of developmental progression. Task-specific analyses evaluated whether developmental patterns differed according to the type of updating task used.

Our Most Popular Resources

Working memory updating performance improved significantly with age, with the largest gains occurring during early to middle childhood (ages 3-8; d = 2.29). Both linear and quadratic models described the developmental trajectory, but the quadratic model provided a better fit, indicating that improvements were steeper in early childhood and gradually slowed during adolescence. Developmental patterns also varied by task. Backward recall tasks demonstrated the strongest age-related improvement (β = .21), whereas n-back and selective updating tasks showed relatively flat developmental trajectories. These findings indicate that estimates of working memory development may depend substantially on the assessment paradigm used.

Copyright © Skyscape. All rights reserved.

Source: Song, Y. and Cheng, C. The developmental trajectories of working memory updating from early childhood to adolescence: A meta-analysis. British Journal of Psychology. 2026; 117(4): 1367-1395. Published: November, 2026. DOI: 10.1111/bjop.70069.



Lecanemab Treatment Produces Divergent Changes in Plasma Biomarkers of Alzheimer's Disease

A longitudinal study of 197 patients receiving lecanemab found significant changes in 34 of 130 plasma biomarkers, with some moving toward levels seen in cognitively unimpaired individuals while others changed in the opposite direction or remained stable. These divergent patterns suggest that amyloid clearance may affect multiple biological pathways differently. Further research is needed to determine whether these biomarkers can reliably guide treatment monitoring and predict clinical outcomes in Alzheimer's disease.

source: The Lancet Neurology

Summary

[Posted 20/Oct/2026]

AUDIENCE: Neurology, Psychiatry

KEY FINDINGS: Lecanemab treatment was associated with heterogeneous changes across plasma biomarkers, indicating that amyloid clearance does not produce a uniform response across biological pathways involved in Alzheimer’s disease. Changes in inflammatory and neurodegeneration-related markers may reflect immune responses to amyloid plaques or treatment-related effects on neuronal and synaptic processes.

These findings suggest that different biomarkers could eventually serve distinct clinical purposes, including monitoring treatment response and estimating prognosis. However, the observational design does not establish that individual biomarker changes predict clinical benefit or adverse outcomes. Further validation is needed before these trajectories can guide treatment decisions in routine practice.

BACKGROUND: Lecanemab, an anti-amyloid antibody, can slow cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. However, its effects on circulating biomarkers associated with neurodegeneration, inflammation, and synaptic function remain incompletely characterized. Understanding these changes could help clinicians assess treatment response and identify biomarkers that may eventually inform prognosis.

DETAILS: This longitudinal cohort study, published in The Lancet Neurology, evaluated changes in 130 plasma protein biomarkers among patients receiving lecanemab as part of routine clinical care at the Washington University Memory Diagnostic Center in St Louis, Missouri. The study included 197 patients who had initiated treatment and were followed for up to two years, with clinical assessments and blood collection approximately every six months. Lecanemab was administered intravenously at 10 mg/kg every two weeks. The comparison groups comprised 1,312 participants with cognitive impairment who had not received anti-amyloid antibody treatment and 458 cognitively unimpaired participants without evidence of amyloid-beta positivity. Investigators examined biomarker trajectories and their associations with treatment exposure, amyloid PET status, and cognitive changes.

Our Most Popular Resources

Of the 130 plasma biomarkers evaluated, 34 demonstrated statistically significant changes during lecanemab treatment after correction for multiple comparisons. The biomarkers followed four distinct patterns.

The first group showed partial normalization, with concentrations moving toward those observed in cognitively unimpaired individuals without amyloid positivity. Examples included phosphorylated tau 217 (p-tau217), microtubule-associated protein tau (MAPT), and glial fibrillary acidic protein (GFAP).

A second group, including amyloid-beta peptides, initially moved toward the reference range but subsequently shifted beyond it, suggesting an overcorrection rather than simple normalization.

A third group showed changes in the opposite direction, moving farther from the concentrations observed in the cognitively unimpaired, amyloid-negative group. These included neuronal pentraxin receptor (NPTXR), neurogranin (NRGN), and triggering receptor expressed on myeloid cells 2 (TREM2).

Other biomarkers, including neurofilament light (NEFL) and apolipoprotein E (APOE), remained comparatively unchanged.

Copyright © Skyscape. All rights reserved.

Source: Mu, R., Hofmann, A., Gong, K., et al. Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study. The Lancet Neurology. 2026; 25(11): 997-1009. Published: November, 2026. DOI: 10.1016/S1474-4422(26)00284-X.



Smartphone-Based Circadian Rhythm Stabilization May Reduce Mood Episode Recurrence

A 12-month randomized trial found that a personalized smartphone app designed to stabilize circadian rhythms was associated with fewer recurrent mood episodes in adults with major depressive disorder or bipolar disorder. The findings support further evaluation of digital circadian interventions as an adjunct to standard psychiatric care.

source: Am J Psychiatry

Summary

[Posted 2/Oct/2026]

AUDIENCE: Psychiatry, Neurology

KEY FINDINGS: In this 12-month randomized trial, a smartphone intervention providing personalized circadian rhythm stabilization feedback was associated with fewer recurrent mood episodes and fewer days spent in recurrent episodes among adults with MDD or BD. The findings support further evaluation of personalized digital chronotherapy as an adjunct to standard psychiatric care. The study was conducted in a relatively small sample, and additional research will be important to assess effectiveness across broader and more diverse patient populations.

BACKGROUND: Recurrence of depressive and bipolar mood episodes remains a major challenge in long-term psychiatric care. Because disruptions in circadian rhythms are associated with mood instability, researchers developed the Circadian Rhythm for Mood (CRM) smartphone app to provide individualized mood forecasts and personalized feedback aimed at stabilizing circadian patterns. This randomized clinical trial evaluated whether the intervention could reduce recurrent mood episodes in adults with major depressive disorder or bipolar disorder.

DETAILS: This multicenter, double-blind, sham-controlled randomized clinical trial included 93 adults with MDD or BD. Participants were randomly assigned to an active CRM app group (47 participants) or a sham-app group (46 participants) for 12 months. The CRM app used passive sensor data and machine-learning algorithms to generate individualized 3-day mood forecasts and personalized circadian rhythm stabilization feedback. The sham app had an identical interface but provided nonactionable feedback generated by a dummy algorithm. The primary outcome was the number of recurrent mood episodes during follow-up.

Our Most Popular Resources

The modified intention-to-treat analysis included 80 participants, with 38 in the active CRM group and 42 in the sham group. The sham group had a significantly higher rate of recurrent mood episodes than the active CRM group, with an incidence rate ratio of 3.39 (95% CI, 1.86-6.17). Cumulative recurrent episode-days per person-year were also greater with the sham intervention, with a duration rate ratio of 2.76 (95% CI, 1.19-6.40). Time to recurrence differed between groups, with a hazard ratio of 3.03 (95% CI, 1.58-5.81). No significant adverse effects were observed.

Copyright © Skyscape. All rights reserved.

Source: Yeom, J. W., Jeong, J., Moon, E., et al. Circadian Rhythm Stabilization App to Prevent Mood Episode Recurrence in Patients With Mood Disorders: A Multicenter, Double-Blind, Sham-Controlled, Randomized Clinical Trial. American Journal of Psychiatry. 2026; 183(9): 657-667. Published: September, 2026. DOI: 10.1176/appi.ajp.20251008.



Depressive Symptoms Associated With Cognitive Impairment in Cerebral Amyloid Angiopathy

A study of 168 adults found that patients with cerebral amyloid angiopathy had substantially more depressive symptoms and poorer cognitive performance than cognitively normal controls. Possible depression was associated with impairment in episodic memory, executive function, and processing speed, and partially mediated the relationship between CAA and cognition. Greater depressive symptoms were also associated with MRI markers of cortical and small-vessel brain injury.

source: Neurology

Summary

[Posted 24/Sep/2026]

AUDIENCE: Neurology, Psychiatry

KEY FINDINGS: People with CAA in this study had substantially more depressive symptoms and poorer cognitive performance than cognitively normal controls. Depressive symptoms explained a small but significant portion of the association between CAA and impairment in episodic memory and executive function, suggesting that mood symptoms may contribute to cognitive difficulties in CAA. Greater depressive symptom severity was also associated with MRI markers of cortical and small-vessel brain injury. Because the study was cross-sectional, the findings do not establish whether CAA-related brain injury causes depression or whether depressive symptoms contribute to subsequent cognitive decline.

BACKGROUND: Cerebral amyloid angiopathy (CAA), a small-vessel disease characterized by β-amyloid deposition in cerebral vessel walls, is associated with cognitive impairment and dementia. Depression can independently affect memory and executive function, but the relationship between depressive symptoms, CAA-related brain injury, and cognition has been less clearly defined. This study examined whether depressive symptoms were associated with cognitive performance in people with CAA and whether depression helped explain the relationship between CAA and cognitive impairment.

DETAILS: Researchers analyzed baseline data from a prospective longitudinal cohort recruited through memory and stroke-prevention clinics at two Canadian centers. The analysis included adults aged ≥55 years with probable CAA and cognitively normal controls. Cognitive performance was evaluated across episodic memory, executive function, and processing speed, while depressive symptoms were assessed using the 15-item Geriatric Depression Scale (GDS-15). A score ≥5 was classified as "possible depression." The primary analysis included 168 participants: 85 with CAA and 83 cognitively normal controls. The mean age was 73.5 years among participants with CAA and 68.8 years among controls. Additional analyses exam-ined relationships between depressive symptoms and CAA-related MRI markers in 81 participants with CAA.

Our Most Popular Resources

Participants with CAA had substantially higher odds of possible depression than controls, with an odds ratio of 15.71 (95% CI, 4.26-80.05; P<0.001). Their GDS-15 scores were also 2.71 times higher than those of controls (95% CI, 2.10-3.51; P<0.001). Possible depression was associated with poorer performance across all three cognitive domains. After adjustment for age, sex, and education, associations were observed for episodic memory (β=-1.03; 95% CI, -1.53 to -0.53; P<0.001), executive function (β=-1.11; 95% CI, -1.65 to -0.58; P<0.001), and processing speed (β=-0.73; 95% CI, -1.24 to -0.21; P=0.006). Mediation analysis suggested that depressive symptoms accounted for 11% of the association between CAA and episodic memory and 9% of the association between CAA and executive function. No significant mediation was observed for processing speed, where depression accounted for approximately 2% of the association.

Among participants with CAA, greater depressive symptom severity was also associated with lower mean cortical thickness, cortical superficial siderosis, and a higher CAA-related small-vessel disease burden. Specifically, the count ratio was 1.33 (95% CI, 1.09-1.62; P=0.005) per SD decrease in cortical thickness, 2.04 (95% CI, 1.35-3.09; P<0.001) for cortical superficial siderosis, and 1.16 (95% CI, 1.00-1.35; P=0.047) for higher CAA small-vessel disease score.

Copyright © Skyscape. All rights reserved.

Source: Nukala, N., Muir, R. T., Beaudin, A. E., et al. Associations Between Cerebral Amyloid Angiopathy, Cognitive Impairment, and Depressive Symptoms. Neurology. 2026; 107(5): e218354. Published: September, 2026. DOI: 10.1212/WNL.0000000000218354.



Neovascular Glaucoma Associated With Increased Long-Term Mortality and Systemic Morbidity

A large TriNetX cohort study found that neovascular glaucoma was associated with increased long-term risks of mortality and systemic complications beyond underlying retinal vascular disease. At 10 years, NVG in patients with proliferative diabetic retinopathy was associated with higher mortality and end-stage renal disease, while NVG in patients with central retinal vein occlusion was associated with higher mortality and stroke risk. The findings highlight the potential value of coordinated ophthalmic and systemic care when NVG develops.

source: Ophthalmology Glaucoma

Summary

[Posted 22/Sep/2026]

AUDIENCE: Ophthalmology, Endocrinology, Internal Medicine

KEY FINDINGS: The development of NVG was associated with additional long-term systemic morbidity and mortality beyond the underlying PDR or CRVO in this large retrospective cohort. The strongest associations included mortality and ESRD among patients with PDR and mortality and stroke among those with CRVO. The findings suggest that development of NVG may identify patients with substantial systemic vascular risk and support closer coordination between ophthalmic and other medical specialties. Because the study was retrospective and based on electronic health records, the observed associations should not be interpreted as evidence that NVG itself directly causes these systemic outcomes.

BACKGROUND: Neovascular glaucoma (NVG) is a serious ocular complication of retinal vascular disease, including proliferative diabetic retinopathy (PDR) and central retinal vein occlusion (CRVO). Although NVG is primarily recognized for its effects on vision and intraocular pressure, less is known about whether its development is associated with additional long-term systemic health risks. This multicenter retrospective cohort study evaluated mortality and major systemic outcomes among adults with PDR or CRVO who did or did not subsequently develop NVG.

DETAILS: The investigators used the TriNetX Research Network, a deidentified electronic health record database containing information from more than 177 million patients across more than 150 healthcare organizations worldwide. Adults older than 40 years with PDR or CRVO were identified and compared according to whether NVG subsequently developed. Patients were propensity-score matched 1:1 based on demographic characteristics and comorbidities. Outcomes were assessed at 1, 5, and 10 years and included all-cause mortality, stroke, myocardial infarction (MI), end-stage renal disease (ESRD), and deep-vein thrombosis (DVT). A total of 1,278 patients with PDR and NVG were matched with 1,278 patients with PDR without NVG. The study also evaluated patients with CRVO and NVG compared with matched CRVO patients without NVG, as well as an NVG cohort compared with a cataract control cohort.

Our Most Popular Resources

Among patients with PDR, development of NVG was associated with higher 10-year mortality (HR, 1.34; 95% CI, 1.14-1.57) and ESRD (HR, 1.43; 95% CI, 1.23-1.67) compared with PDR without NVG. Ten-year survival was 60.4% in the PDR + NVG group compared with 68.4% in the PDR without NVG group. Among patients with CRVO, those who developed NVG had higher 10-year mortality (HR, 1.61; 95% CI, 1.17-2.20) and stroke risk (HR, 1.86; 95% CI, 1.19-2.90). Differences in MI and ESRD were not statistically significant in this comparison, and DVT risk was also not significantly different. When PDR + NVG was compared directly with CRVO + NVG, the PDR + NVG group had higher 10-year risks of mortality (HR, 1.56; 95% CI, 1.17-2.07), MI (HR, 1.94; 95% CI, 1.13-3.32), and ESRD (HR, 4.04; 95% CI, 2.43-6.73). Compared with the cataract control cohort, NVG was associated at 10 years with higher risks of mortality (HR, 2.66; 95% CI, 2.40-2.94), stroke (HR, 2.17; 95% CI, 1.85-2.54), MI (HR, 1.89; 95% CI, 1.60-2.23), and ESRD (HR, 3.34; 95% CI, 2.89-3.88).

Copyright © Skyscape. All rights reserved.

Source: Margolis, R., Vasu, P., and Dorairaj, S. K. Long-Term Risk of Mortality and Systemic Morbidity in Neovascular Glaucoma: A Multicenter Retrospective Cohort Study. Ophthalmology Glaucoma. 2026; 9(5): 517-526. Published: September-October, 2026. DOI: 10.1016/j.ogla.2026.01.017.



Specialty: 

Breaking Medical News Cardiology Dermatology Emergency Medicine Endocrinology Family Medicine Gastroenterology General Interests General Surgery Hematology/Oncology Infectious Disease Internal Medicine Nephrology Neurology Nursing Ob/Gyn Ophthalmology Palliative Hospice Pediatrics Pharmacy Psychiatry